vla1601
Vaccineexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 24, 2018 (NCT03425149)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Zika virusImmunity, active
immunity, active - zika virus
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06334393 | Phase 1 | Mar 25, 2024 | Valneva |
| NCT03425149 | Phase 1 | Feb 24, 2018 | Emergent BioSolutions, Valneva |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Valneva | For profit | 2 | 2 | 1 | 2018 |
| Emergent BioSolutions | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1